Evidence map›Paper›PMID 41745104›Full record

ReviewDiseases (Basel, Switzerland)2026

Detection for New Biomarkers of Tuberculosis Infection Activity Using Machine Learning Methods.

Anna An Starshinova, Adilya Sabirova, Olesya Koroteeva, Igor Kudryavtsev, Artem Rubinstein, Arthur Aquino, Andrey S Trulioff, Ekaterina Belyaeva, Anastasia Kulpina, Raul A Sharipov and 6 more

Abstract readReview
In one paragraph

Review in Diseases (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Anna An StarshinovaDepartment of Mathematics and Computer Science, Saint Petersburg State University, 199034 Saint Petersburg, Russia.ORCID 0000-0002-9023-6986
Adilya SabirovaDepartment of Mathematics and Computer Science, Saint Petersburg State University, 199034 Saint Petersburg, Russia.
Olesya KoroteevaDepartment of Medicine, Almazov National Medical Research Center of the Ministry of Health of the Russian Federation, 197341 Saint Petersburg, Russia.
Igor KudryavtsevInstitute of Experimental Medicine, Acad. Pavlov St. 12, 197376 Saint Petersburg, Russia.
Artem RubinsteinInstitute of Experimental Medicine, Acad. Pavlov St. 12, 197376 Saint Petersburg, Russia.ORCID 0000-0002-8493-5211
Arthur AquinoDepartment of Medicine, Almazov National Medical Research Center of the Ministry of Health of the Russian Federation, 197341 Saint Petersburg, Russia.ORCID 0000-0001-6516-7184
Andrey S TrulioffMedical Department, Bashkir State Medical University, 450000 Ufa, Russia.
Ekaterina BelyaevaDepartment of Mathematics and Computer Science, Saint Petersburg State University, 199034 Saint Petersburg, Russia.
Anastasia KulpinaDepartment of Mathematics and Computer Science, Saint Petersburg State University, 199034 Saint Petersburg, Russia.
Raul A SharipovMedical Department, Bashkir State Medical University, 450000 Ufa, Russia.
Ravil K TukfatullinMedical Department, Bashkir State Medical University, 450000 Ufa, Russia.
Nikolay Y NikolenkoThe Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Department of Health, 127006 Moscow, Russia.ORCID 0000-0002-1071-2680
Anton MikhalevArtificial Intelligence Center, Siberian Federal University, 660041 Krasnoyarsk, Russia.ORCID 0000-0002-8986-5953
Andrey A SavchenkoFederal Research Center «Krasnoyarsk Science Center» of the Siberian Branch of the Russian Academy of Sciences, Scientific Research Institute of Medical Problems of the North, 660036 Krasnoyarsk, Russia.ORCID 0000-0001-5829-672X
Alexandr BorisovFederal Research Center «Krasnoyarsk Science Center» of the Siberian Branch of the Russian Academy of Sciences, Scientific Research Institute of Medical Problems of the North, 660036 Krasnoyarsk, Russia.
Dmitry KudlayDepartment of Pharmacology, Institute of Pharmacy, Sechenov University, 119002 Moscow, Russia.ORCID 0000-0003-1878-4467

Funding

Ministry of Science and Higher Education of the Russian Federation 075-15-2025-013
6 · The paper itself

Abstract

BACKGROUND/

objectivesLatent tuberculosis infection (LTBI) represents a critical reservoir for subsequent development of active tuberculosis (ATB) and poses significant challenges for early diagnosis and disease prevention. Traditional immunological assays, such as interferon-gamma release assays (IGRAs), are limited in their ability to reliably distinguish LTBI from ATB. Recent advances in high-throughput omics technologies and machine learning (ML) approaches offer new opportunities for precise, biomarker-based differential diagnostics.

methodsTranscriptomic and proteomic profiling of host immune responses has revealed reproducible gene and protein signatures associated with LTBI and ATB. The integration of ML techniques-including feature selection, dimensionality reduction, multimodal learning, and explainable AI-facilitates the construction of robust diagnostic models. Single-modality signatures, derived from RNA-seq, microarrays, or proteomic assays, are complemented by multimodal approaches that incorporate soluble mediators, immunological readouts, and imaging-derived features. Deep learning frameworks, such as convolutional neural networks and transformer-based architectures, enhance the extraction of complex molecular and structural patterns from high-dimensional datasets.

resultsML-driven analyses of transcriptomic and proteomic data consistently outperform conventional immunological tests in terms of sensitivity, specificity, and clinical applicability. Multimodal integration further improves diagnostic accuracy and robustness. These advances support the translational development of concise, quantitative reverse transcription PCR (qRT-PCR)-based biomarker panels suitable for routine clinical application, enabling early and reliable differentiation between LTBI and ATB. Overall, the combination of high-throughput omics and AI-based analytical frameworks provides a promising pathway for enhancing global tuberculosis diagnostics.

conclusionsThis review provides a structured and critical synthesis of transcriptomic and proteomic biomarker research for LTBI and ATB discrimination, with a particular emphasis on machine learning-based analytical frameworks. Unlike previous narrative reviews, we systematically compare data-generating platforms, modelling strategies, validation approaches, and sources of heterogeneity across studies. We further identify key translational barriers, including cohort homogeneity, platform dependency, and limited external validation, and propose directions for future research aimed at improving clinical applicability.

Indexed as

extracellular vesiclesimmune biomarkersimmunodiagnosticsinterferon signaturelatent tuberculosis infectionmultidrug-resistant tuberculosisMycobacterium tuberculosisPET/CT imagingpreclinical stagetranscriptomics

Identifiers

PMID41745104
PMCPMC12939407

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.